Skystar's New Vaccine Facility in Huxian Passes Initial GMP

Skystar's New Vaccine Facility in Huxian Passes Initial GMP
Certification 
New Vaccine Facility Includes Animal and Aquaculture Vaccine Lines;
At Maximum Potential Production Capacity, the New Facility Is
Projected to Be Capable of Manufacturing an Estimated $15 Million to
$17 Million of Combined Annual Revenue 
XI'AN, CHINA -- (Marketwire) -- 11/13/12 --   Skystar
Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the
"Company"), a China-based manufacturer and distributor of veterinary
medicines, vaccines, micro-organisms and feed additives, today
announced that China's Ministry of Agriculture (MOA) Good
Manufacturing Process "GMP" experts have certified that Skystar's new
vaccine facility in Huxian, China is 'Stage 1' GMP compliant. A
public record of the MOA Inspectors' decision is posted on the China
Institute of Veterinary Drug Control's website at:
http://www.ivdc.gov.cn/zzys/gmpys/201209/t20120924_39284.htm. 
The inspection team has recommended to the MOA's Office of the
Working Committee that it should go forward with Stage 2 of the GMP
certification process. Stage 2, the final stage of the GMP
certification process, requires production line samples of the
Company's various vaccine products to be submitted to the MOA for
testing. The Committee will then determine if the production line
samples meet current GMP production standards. At the successful
completion of this process, Skystar must then apply for and receive
drug control numbers for each product before vaccine production at
the new facility can begin.  
At maximum potential production capacity, the new facility is
projected to be capable of manufacturing an estimated $15 million to
$17 million of combined annual revenue with gross margins near 70% on
an annual basis. The Company anticipates launching 10 new vaccine
products in 2013 and a total of 20 to 30 products in total over the
next 5 years.  
Mr. Weibing Lu, Skystar Bio-Pharmaceutical's Chairman and Chief
Executive Officer, commented on the foregoing: "The Company is moving
its newly built vaccine plant towards full GMP certification. The
increased manufacturing capability will play an integral part of
Skystar's growth strategy in the upcoming years as the Company
focuses on expanding its footprint, customer base and verticals." 
To be added to the Company's email distribution for future news
releases, please send your request to skystar@grayling.com. 
About Skystar Bio-Pharmaceutical Company
 Skystar is a China-based
developer and distributor of veterinary healthcare and medical care
products. Skystar has four product lines (veterinary medicines,
micro-organisms, vaccines and feed additives) and over 284 products.
Skystar has formed strategic sales distribution networks covering 29
provinces throughout China. For additional information, please visit
http://www.skystarbio-pharmaceutical.com. 
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
 Certain of the statements made in the press release
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by the use of forward-looking terminology such as
"believe," "expect," "may," "will," "should," "project," "plan,"
"seek," "intend," or "anticipate" or the negative thereof or
comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information
regarding the progress of new product development. Actual results
could differ materially from the expectations reflected in such
forward-looking statements as a result of a variety of factors,
including the risks associated with the Company's ability to receive
timely certification and related government approvals, its ability to
reach full production capabilities as projected and to capitalize and
generate expected revenue following GMP certifications, its ability
to continue additional sales and related expenses in connection with
the anticipated increased production levels effect of changing
economic conditions in The People's Republic of China, variations in
cash flow, reliance on collaborative retail partners and on new
product development, variations in new product development, risks
associated with rapid technological change, and the potential of
introduced or undetected flaws and defects in products, and other
risk factors detailed in reports filed with the Securities and
Exchange Commission from time to time. 
Contacts: 
Skystar Bio-Pharmaceutical Company
Scott Cramer
Director - Corporate Development and U.S. Representative
(407) 645-4433 
Grayling  
Investor Relations
Christopher Chu 
(646) 284-9426
christopher.chu@grayling.com 
 
 
Press spacebar to pause and continue. Press esc to stop.